Osteoporosis | Current Treatment | US | 2016

Publish date: June 2019

Login to access report

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with these therapies usually relegated to later lines because of their higher prices, duration restrictions, and/or injectable mode of delivery. Additionally, osteoporosis diagnosis and compliance rates are low mainly because of patients’ concern about rare but serious side effects of medications, the asymptomatic nature of the disease, and a limited understanding of the seriousness of osteoporosis. However, despite these obstacles, select branded therapies have achieved significant sales. Opportunities exist for emerging agents in osteoporosis, but these agents will likely face challenges.

QUESTIONS ANSWERED

  • What is the current patient share of branded therapies such as Eli Lilly’s Forteo and Amgen’s Prolia?
  • What effect has the launch of Radius Health’s Tymlos had on treatment decisions?
  • What are the anticipated changes in prescribing patterns over the next 12 months?
  • What effect do physicians think the launch of Amgen / UCB’s Evenity would have? Which patients would most likely be prescribed Evenity? Which current therapies would be most affected by Evenity’s launch?
  • What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of osteoporosis?
  • What are the drivers and constraints determining prescribing practices for osteoporosis?

Scope

  • Geography: United States.
  • Primary Research: Survey of 100 U.S. rheumatologists / endocrinologists / PCPs.
  • Key Drugs Covered: Prolia, Tymlos, Forteo, oral and IV bisphosphonates, SERMs, HRT, calcitonin.